Biotech & Finance Forum

The Biotech & Finance Forum (http://www.e-unlimited.com/Munich2003/Biotech) is an exclusive European Investment Forum designed to gather a select group of Entrepreneurs from fast-growing unlisted biotech companies, top International Venture Capitalists, leading corporates, and financial institutions from the biotechnology sector.

This initiative is supported by the European Commission and EuropaBio, and provides the ideal setting for developing business, meeting potential investors and generating high-level networking.
Application and Selection Process for Interested Companies.,60 Selected companies will have the opportunity to present in 2 Main Stream Presentation Sessions, where companies will be clustered according to their sector focus. In addition, the Forum will host 2 of Europe Unlimited's highly acclaimed Sector Summits, focussing on Therapeutics & Drug Discovery respectively. Here companies can present to investors with a clear specialisation and interest in these sectors, as well as find out about the vision of leading VCs and Corporates in these sectors. There is a special sub-section for listed companies that wish to present. (http://www.e-unlimited.com/Munich2003/Biotech/programme.htm)
The first selection of companies will be made between the 9th January and 13 January. Please note that companies that apply before January 9th will be given preference, and interest among companies in presenting to investors has been very high. Only 60 companies from those applying will be selected to present to investors. A first come first served policy will apply - therefore companies that apply early will have an increased chance of being selected (providing of course that their application is of the required quality).
If you are interested in presenting your company during the 5th Biotechnology & Finance Forum, please send an email to ,mailto:[e-mail]
The Advisory Board includes leading names in the biotech sector, such as Mike Ward from Critical I, George Morris, Waldemar Kutt from the European Commission, Prof. Horst Domdey from Bio-M, and Hugo Schepens from EuropaBio.
Delegates Attending the Biotech & Finance Forum include Dr Peter Heinrich, CEO, Medigene; Professor Lucas, Director, International Science and Technology Development, Biogene; Bruno Hansen, Director Life Sciences, DG Research; Professor Domdey, Managing Director, Bio-M; Patrick Doyle, Global Alliances Director, Hofmann Roche; Michel Baijot, VP Business Development, Innogenetics NV; Michel Hubert, VP Business Development, Transgene; Alain Maïore, General Partner, Ventech; Hubert Birner, General Partner TVM; Dr Kalevi Kurkijärvi, CEO Bio Fund; Denis Lucquin, General Partner Life Sciences, Sofinnova Partners; Joel Besse, Senior Principal, Atlas Venture; Dr Jane Fisken, Head of Global Life Sciences, Dresdner Kleinwort Wasserstein; Erik Schlick, 3i Healthcare Germany.
For further information or assistance please contact:
Bernardita Cárdenas,Research Analysts,Europe Unlimited SA,Place E. Flagey 7, 1050 Brussels, Belgium,Tel:[phone] (direct) Fax:[phone],Email:[e-mail]

Länder

Belgium, Germany